Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.34 |
| ▸ | ADH1B | P00325 | 1/20 | 0.34 |
| ▸ | ADH1C | P00326 | 1/20 | 0.34 |
| ▸ | ADH1A | P07327 | 1/20 | 0.34 |
| ▸ | ADH4 | P08319 | 1/20 | 0.34 |
| ▸ | ADH7 | P40394 | 1/20 | 0.34 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28910560 | 1.00 | OPRM1 (0.38) | OPRM1SPHK1LMNAFAAHDNM1 | |
| SCHEMBL21722572 | 0.98 | OPRM1 (0.37) | OPRM1SPHK1LMNAFAAHDNM1 | |
| SCHEMBL29101786 | 0.96 | OPRM1 (0.38) | OPRM1SPHK1LMNAFAAHDNM1 | |
| SCHEMBL23671854 | 0.88 | DNM1 (0.34) | OPRM1SPHK1LMNAFAAHDNM1 | |
| SCHEMBL9063918 | 0.85 | OPRM1 (0.42) | OPRM1SPHK1LMNADNM1ADH1B | |
| SCHEMBL3022847 | 0.83 | OPRM1 (0.41) | OPRM1SPHK1LMNADNM1ADH1B | |
| SCHEMBL28571242 | 0.82 | OPRM1 (0.34) | OPRM1SPHK1LMNADNM1ADH1B | |
| SCHEMBL8984406 | 0.81 | ZDHHC7 (0.37) | OPRM1LMNADNM1SMPD1TSHR | |
| SCHEMBL10598235 | 0.81 | ZDHHC7 (0.37) | OPRM1LMNADNM1SMPD1TSHR | |
| SCHEMBL28527318 | 0.81 | ZDHHC7 (0.37) | OPRM1LMNADNM1SMPD1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1212339-B1 | 2'-O-ACETAMIDO MODIFIED MONOMERS AND OLIGOMERS | ISIS PHARMACEUTICALS INC (US) | 2008-12-31 | — | — | EP | disclosed |
| US-6991902-B2 | Nucleobase heterocyclic combinatorialization | ISIS PHARMACEUTICALS, INC. (US) | 2006-01-31 | — | — | US | disclosed |
| US-6942966-B1 | libraries formed by permutations; combinatorial chemistry; drug screening | ISIS PHARMACEUTICALS, INC. (US) | 2005-09-13 | — | — | US | disclosed |
| US-6933288-B2 | Pyranosyl cytosines: pharmaceutical formulations and methods | ISIS PHARMACEUTICALS, INC. | 2005-08-23 | — | — | US | disclosed |
| EP-1223173-B1 | Novel 2'-O-alkyl nucleosides and phosphoramidites processes for the preparation and uses thereof | ISIS PHARMACEUTICALS INC (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20050106598-A1 | Novel peptide-conjugated oligomeric compounds | ISIS PHARMACEUTICALS, INC. | 2005-05-19 | — | — | US | disclosed |
| US-6893815-B1 | Nucleobase heterocyclic combinatorialization | ISIS PHARMACEUTICALS, INC. (US) | 2005-05-17 | — | — | US | disclosed |
| US-6878805-B2 | Peptide-conjugated oligomeric compounds | ISIS PHARMACEUTICALS, INC. (US) | 2005-04-12 | — | — | US | disclosed |
| EP-1499627-A2 | NUCLEASE RESISTANT CHIMERIC OLIGONUCLEOTIDES | ISIS Pharmaceuticals, Inc. (US) | 2005-01-26 | — | — | EP | disclosed |
| US-20040266706-A1 | Cross-linked oligomeric compounds and their use in gene modulation | ISIS PHARMACEUTICALS, INC. | 2004-12-30 | — | — | US | disclosed |
| US-5519134-A | ANTIINFLAMMATORY AGENTS | ISIS PHARMACEUTICALS, INC. (US) | 1996-05-21 | — | — | US | disclosed |
| US-5506351-A | Process for the preparation of 2'-O-alkyl guanosine and related compounds | ISIS PHARMACEUTICALS (US) | 1996-04-09 | — | — | US | disclosed |
| EP-0635023-A4 | COVALENTLY CROSS-LINKED OLIGONUCLEOTIDES. | ISIS PHARMACEUTICALS INC (US) | 1996-03-20 | — | — | EP | disclosed |
| WO-1995023160-A1 | NOVEL PHOSPHORAMIDATE AND PHOPHOROTHIOAMIDATE OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 1995-08-31 | — | — | WO | disclosed |
| WO-1995021184-A1 | SUBSTITUTED PURINES AND OLIGONUCLEOTIDE CROSS-LINKING | ISIS PHARMACEUTICALS, INC. (US) | 1995-08-10 | — | — | WO | disclosed |
| WO-1995018623-A1 | OLIGOMERIC COMPOUNDS HAVING NITROGEN-CONTAINING LINKAGES | ISIS PHARMACEUTICALS, INC. (US) | 1995-07-13 | — | — | WO | disclosed |
| WO-1995018792-A1 | PYRROLIDINE-CONTAINING MONOMERS AND OLIGOMERS | ISIS PHARMACEUTICALS, INC. (US) | 1995-07-13 | — | — | WO | disclosed |
| WO-1995018820-A1 | MONOMERIC DIOLS AND PHOSPHATE LINKED OLIGOMERS FORMED THEREFROM | ISIS PHARMACEUTICALS, INC. (US) | 1995-07-13 | — | — | WO | disclosed |
| EP-0635023-A1 | COVALENTLY CROSS-LINKED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1995-01-25 | — | — | EP | disclosed |
| WO-1993018052-A1 | COVALENTLY CROSS-LINKED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1993-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266706-A1 | Cross-linked oligomeric compounds and their use in gene modulation | SNRPE, DCLRE1A, PHAX | OPRM1 1799/4885SPHK1 4262/4885LMNA 1628/4885 |
| US-20050106598-A1 | Novel peptide-conjugated oligomeric compounds | IAPP, NGLY1, TAP1 | OPRM1 2867/4885SPHK1 4264/4885LMNA 2480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.